The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.
|Articles|April 28, 2021
The Mainstream Patient: April 28, 2021
Author(s)Morgan Petronelli
This week’s edition of The Mainstream Patient features stories on cryptocurrency for cosmetic procedures, tattoo removal, full-size sunscreen in carry-on bags, using ice on the face, plus more.
Advertisement
In this week’s edition, Allure provides an in-depth guide to common skin conditions that primarily affect people with darker skin types. Also, Glamour explains everything there is to know before getting tattoo removal, and Self provides some clarification on recent news about the TSA possibly allowing full-size sunscreen in carry-on bags. Harper’s Bazaar features a story on how some plastic surgeons are now accepting cryptocurrency payment for procedures, and Vogue highlights the new trend of putting ice on the face. Finally, Shape writes about a new deodorant from Degree that is tailored for people with disabilities.
Advertisement
Related to this article
The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.
A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.
The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.
This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.
Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis
3
Personalized Prescription Skin Care: Curology’s Whitney Tolpinrud, MD, on the Evolution of Virtual Dermatology
4
Previewing the 2026 Fall Clinical Dermatology Conference
5